These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 18425770)

  • 1. AKT as locus of fragility in robust cancer system.
    Radisavljevic Z
    J Cell Biochem; 2008 Aug; 104(6):2071-7. PubMed ID: 18425770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locus of fragility in robust breast cancer system.
    Radisavljevic Z
    J Cell Biochem; 2004 Aug; 92(5):1020-4. PubMed ID: 15258923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AKT as locus of cancer angiogenic robustness and fragility.
    Radisavljevic Z
    J Cell Physiol; 2013 Jan; 228(1):21-4. PubMed ID: 22585603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells.
    Dai J; Peng L; Fan K; Wang H; Wei R; Ji G; Cai J; Lu B; Li B; Zhang D; Kang Y; Tan M; Qian W; Guo Y
    Oncogene; 2009 Sep; 28(38):3412-22. PubMed ID: 19597469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AKT as locus of cancer positive feedback loops and extreme robustness.
    Radisavljevic Z
    J Cell Physiol; 2013 Mar; 228(3):522-4. PubMed ID: 22833426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AKT as locus of cancer multidrug resistance and fragility.
    Radisavljevic Z
    J Cell Physiol; 2013 Apr; 228(4):671-4. PubMed ID: 22886615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors.
    Porta C; Figlin RA
    J Urol; 2009 Dec; 182(6):2569-77. PubMed ID: 19836781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy.
    García-Maceira P; Mateo J
    Oncogene; 2009 Jan; 28(3):313-24. PubMed ID: 18978810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Akt signaling and cancer: surviving but not moving on.
    Toker A; Yoeli-Lerner M
    Cancer Res; 2006 Apr; 66(8):3963-6. PubMed ID: 16618711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways.
    Guo C; Gasparian AV; Zhuang Z; Bosykh DA; Komar AA; Gudkov AV; Gurova KV
    Oncogene; 2009 Feb; 28(8):1151-61. PubMed ID: 19137016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen and progestin regulate metastasis through the PI3K/AKT pathway in human ovarian cancer.
    Hua K; Feng W; Cao Q; Zhou X; Lu X; Feng Y
    Int J Oncol; 2008 Nov; 33(5):959-67. PubMed ID: 18949358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The behavior of endothelial cells on polyurethane nanocomposites and the associated signaling pathways.
    Hung HS; Wu CC; Chien S; Hsu SH
    Biomaterials; 2009 Mar; 30(8):1502-11. PubMed ID: 19118895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma.
    Huang Y; Hua K; Zhou X; Jin H; Chen X; Lu X; Yu Y; Zha X; Feng Y
    Cell Res; 2008 Jul; 18(7):780-91. PubMed ID: 18574502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting AKT signaling sensitizes cancer to cellular immunotherapy.
    Hähnel PS; Thaler S; Antunes E; Huber C; Theobald M; Schuler M
    Cancer Res; 2008 May; 68(10):3899-906. PubMed ID: 18483275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Filamin A is a novel caveolin-1-dependent target in IGF-I-stimulated cancer cell migration.
    Ravid D; Chuderland D; Landsman L; Lavie Y; Reich R; Liscovitch M
    Exp Cell Res; 2008 Sep; 314(15):2762-73. PubMed ID: 18598695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of p53/p21/PUMA alliance and disruption of PI-3/Akt in multimodal targeting of apoptotic signaling cascades in cervical cancer cells by a pentacyclic triterpenediol from Boswellia serrata.
    Bhushan S; Malik F; Kumar A; Isher HK; Kaur IP; Taneja SC; Singh J
    Mol Carcinog; 2009 Dec; 48(12):1093-108. PubMed ID: 19544329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug resistance mediated by survival- and growth-promoting signaling pathways].
    Fujita N
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):567-71. PubMed ID: 19381028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KAI1/CD82 decreases Rac1 expression and cell proliferation through PI3K/Akt/mTOR pathway in H1299 lung carcinoma cells.
    Choi UJ; Jee BK; Lim Y; Lee KH
    Cell Biochem Funct; 2009 Jan; 27(1):40-7. PubMed ID: 19107873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AKT as locus of cancer phenotype.
    Radisavljevic Z
    J Cell Biochem; 2015 Jan; 116(1):1-5. PubMed ID: 25164873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ankyrin repeat and suppressor of cytokine signaling (SOCS) box-containing protein (ASB) 15 alters differentiation of mouse C2C12 myoblasts and phosphorylation of mitogen-activated protein kinase and Akt.
    McDaneld TG; Spurlock DM
    J Anim Sci; 2008 Nov; 86(11):2897-902. PubMed ID: 18641171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.